 |
|
Study: Delaying evolution of drug resistance in malaria parasite possible
September 05, 2008GAINESVILLE, Fla. --- There's no magic bullet for wiping out malaria, but a new study offers strong support for a method that effectively delays the evolution of drug resistance in malaria parasites, a University of Florida researcher says.
David Smith, associate director of disease ecology at UF's Emerging Pathogens Institute, said the study will guide scientists and policy makers in extending the longevity of current artemisinin-based malaria drugs combined with partner drugs. Smith is a co-author of a report on the study, scheduled to publish online this week in the Proceedings of the National Academy of Sciences and in print on Sept. 16.
Smith collaborated with lead author Maciej Boni of Resources for the Future and Princeton University, and Ramanan Laxminarayan, also with RFF, to create mathematical models assessing the strategic effectiveness and clinical outcomes of using one, two and three first-line drug therapies to treat malaria within a population over a 20-year period. Their results show that using two or three drugs simultaneously reduced the total clinical cases and number of failed treatments , and slowed the rate at which drug-resistant genes spread within the parasites that cause malaria: Plasmodium falciparum, P. vivax, P. malariae and P. ovale.
"The models indicate that we can slow the evolution of resistance to current artemisinin-based therapies if nations use them in combination with two or more partner drugs," Smith said. "Currently, most nations don't do this. They use one therapy at a time, wait for it to fail, and then switch to a different therapy."
Artemisinin-combined therapies, or ACTs, are currently not widely implemented due to operational challenges and expense, Smith said. But he said the study offers compelling evidence for global leaders to collaborate and overcome these issues.
"This is not to say that implementing multiple first-line therapies solves all of our malaria problems," Boni said. "Anti-malarial drug development needs to continue so that we have novel and highly effective anti-malarials that can be plugged into the recommended strategy of deploying multiple therapies."
In the past century, chloroquine and sulfadoxine-pyrimethamine were widely used to combat malaria, but the parasites eventually evolved resistance leading to the drugs' failure. Artemesinin drugs, derived from the herb Artemisia annua, are relatively new and the malaria parasite does not yet appear to have a resistance to it. They work by triggering chemical reactions which damage the Plasmodium parasite.
"We don't have anything in the pipeline after ACTs, and it's basically just a matter of time until drug resistance evolves and artemisinin also fails," Smith said. "So the question becomes how do we keep ACTs in our arsenal for as long as effectively possible?"
The researchers' models also show that cycling through single drugs accelerated the rate at which malaria parasites evolved drug resistance. Smith said this occurred because cycling a single drug degraded the parasite's average fitness, which made it easier for drug-resistant genes to spread throughout the parasite population.
The cycling models predicted a declining therapeutic value of a single drug within 3.54 years, versus a longer effective therapeutic value of 9.95 years when three drugs were used in equal proportions within a population. The research was funded in part by grants from the Bill and Melinda Gates Foundation, and the National Institutes of Health.
"Using multiple first-line drugs reduces the selection pressure for resistance to a single drug," Smith said. "This is one way to make the ACTs last longer and benefit more people."
Co-author Laxminarayan, a senior research fellow at RFF, said ACTs are the best treatment option for malaria, now as well as in the foreseeable future.
"Novel treatment strategies improve our ability to delay the emergence of drug resistance without the need to deny treatment," Laxminarayan said.
Wil Milhous, associate dean for research at the University of South Florida's College of Public Health, said the research is "clearly a superb breakthrough in mathematical modeling applied to malaria drug deployment." Milhous has worked to develop new drugs for malaria for more than 25 years and is unaffiliated with the study.
"We have done the math in drug development, but only in terms of the cost of goods for drug combinations to include advanced preclinical and clinical testing. These are extremely time-consuming and costly but critical to regulatory approval," Milhous said. "Now we have a highly quantitative reality check that poor implementation strategies doom drugs to failure."
University of Florida
"The models indicate that we can slow the evolution of resistance to current artemisinin-based therapies if nations use them in combination with two or more partner drugs," Smith said. "Currently, most nations don't do this. They use one therapy at a time, wait for it to fail, and then switch to a different therapy."
Artemisinin-combined therapies, or ACTs, are currently not widely implemented due to operational challenges and expense, Smith said. But he said the study offers compelling evidence for global leaders to collaborate and overcome these issues.
"This is not to say that implementing multiple first-line therapies solves all of our malaria problems," Boni said. "Anti-malarial drug development needs to continue so that we have novel and highly effective anti-malarials that can be plugged into the recommended strategy of deploying multiple therapies."
In the past century, chloroquine and sulfadoxine-pyrimethamine were widely used to combat malaria, but the parasites eventually evolved resistance leading to the drugs' failure. Artemesinin drugs, derived from the herb Artemisia annua, are relatively new and the malaria parasite does not yet appear to have a resistance to it. They work by triggering chemical reactions which damage the Plasmodium parasite.
"We don't have anything in the pipeline after ACTs, and it's basically just a matter of time until drug resistance evolves and artemisinin also fails," Smith said. "So the question becomes how do we keep ACTs in our arsenal for as long as effectively possible?"
The researchers' models also show that cycling through single drugs accelerated the rate at which malaria parasites evolved drug resistance. Smith said this occurred because cycling a single drug degraded the parasite's average fitness, which made it easier for drug-resistant genes to spread throughout the parasite population.
The cycling models predicted a declining therapeutic value of a single drug within 3.54 years, versus a longer effective therapeutic value of 9.95 years when three drugs were used in equal proportions within a population. The research was funded in part by grants from the Bill and Melinda Gates Foundation, and the National Institutes of Health.
"Using multiple first-line drugs reduces the selection pressure for resistance to a single drug," Smith said. "This is one way to make the ACTs last longer and benefit more people."
Co-author Laxminarayan, a senior research fellow at RFF, said ACTs are the best treatment option for malaria, now as well as in the foreseeable future.
"Novel treatment strategies improve our ability to delay the emergence of drug resistance without the need to deny treatment," Laxminarayan said.
Wil Milhous, associate dean for research at the University of South Florida's College of Public Health, said the research is "clearly a superb breakthrough in mathematical modeling applied to malaria drug deployment." Milhous has worked to develop new drugs for malaria for more than 25 years and is unaffiliated with the study.
"We have done the math in drug development, but only in terms of the cost of goods for drug combinations to include advanced preclinical and clinical testing. These are extremely time-consuming and costly but critical to regulatory approval," Milhous said. "Now we have a highly quantitative reality check that poor implementation strategies doom drugs to failure."
University of Florida
Malaria Current Events and Malaria News RSSU.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
DNA barcodes: Creative new uses span health, fraud, smuggling, history, more
The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others.
PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines
Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa.
Global challenges and opportunities in fighting HIV/AIDS and neglected diseases
Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs.
Media availability: The role of biomedical research in malaria eradication
Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year.
Ineffective monotherapies common in high-burden malarious countries
ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.
New tool promises more accurate antimalarial drug dosing
Scientists at LSTM have developed a tool to support the development of appropriate age-based dosing regimens for malaria drugs.
Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
More Malaria Current Events and Malaria News Articles
 |
The Making of a Tropical Disease: A Short History of Malaria (Johns Hopkins Biographies of Disease) by Randall M. Packard (Author) Malaria sickens hundreds of millions of people -- and kills one to three million -- each year. Despite massive efforts to eradicate the disease, it remains a major public health problem in poorer tropical regions. But malaria has not always been concentrated in tropical areas. How did other regions control malaria and why does the disease still flourish in some parts of the globe? From Russia to Bengal to Palm Beach, Randall Packard's far-ranging narrative traces the natural and social forces that help malaria spread and make it deadly. He finds that war, land development, crumbling health systems, and globalization -- coupled with climate change and changes in the distribution and flow of water -- create conditions in which malaria's carrier mosquitoes thrive. The combination of... |
 |
The Malaria Capers : More Tales of Parasites and People, Research and Reality by Robert S. Desowitz (Author) "Reads like a murder mystery. . . . [Desowitz] writes with uncommon lucidity and verse, leaving the reader with a vivid understanding of malaria and other tropical diseases, and the ways in which culture, climate and politics have affected their spread and containment."—New York Times Why, Robert S. Desowitz asks, has biotechnical research on malaria produced so little when it had promised so much? An expert in tropical diseases, Desowtiz searches for answers in this provocative book. . |
![GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy]](http://ecx.images-amazon.com/images/I/219e7hJvowL._SL160_.jpg) |
GIANTmicrobes: Malaria (Plasmodium Falciparum) [Toy] by Giant Microbes GIANTmicrobes are fun and educationala great way to learn about various health topics and the microscopic critters that are found in and around us. Each microbe character is 5-7 in size--over a million times their actual size! Perfect for teachers, parents and budding scientiststhey also make humorous gifts. Each microbe comes with an information tag including scientific name, an image of the actual microbe, and a mini history and science lesson. Not suitable for children under 3 years. Our products are made by top manufacturers who care about toy safety, quality and value. Your order will ship factory fresh directly from our warehouse to your door. We carefully inspect and beautifully package every order before shipment to ensure that you receive high quality products that are... |
 |
Humanity's Burden: A Global History of Malaria (Studies in Environment and History) by James L.A. Webb Jr. (Author) Humanity's Burden provides a panoramic overview of the history of malaria. It traces the long arc of malaria out of tropical Africa into Eurasia, its transfer to the Americas during the early years of the Columbian exchange, and its retraction from the middle latitudes into the tropics since the late nineteenth century. Adopting a broadly comparative approach to historical patterns and processes, it synthesizes research findings from the natural and social sciences and weaves these understandings into a narrative that reaches from the earliest evidence of malaria infections in tropical Africa up to the present. Written in a style that is easily accessible to non-specialists, it considers the significance of genetic mutations, diet, lifestyle, migration, warfare, palliative and curative... |
 |
Compiled 1981-1984 by Malaria! |
 |
Malaria: Fever Wars Starring: Artist Not Provided |
 |
First Comes Love, Then Comes Malaria: How a Peace Corps Poster Boy Won My Heart and a Third World Adventure Changed My Life by Eve Brown-Waite (Author) In this laugh-out-loud funny memoir, a pampered city girl falls head over little black heels in love with a Peace Corps poster boy and follows him —literally–to the ends of the earth. Eve Brown always thought she would join the Peace Corps someday, although she secretly worried about life without sushi, frothy coffee drinks and air conditioning. But with college diploma in hand, it was time to put up or shut up. So with some ambivalence she arrives at the Peace Corps office–sporting her best safari chic attire –to casually look into the steps one might take if one were to become a global humanitarian, a la Angelina Jolie. But when Eve meets John, her dashing young Peace Corps recruiter, all her ambivalence flies out the window. She absolutely must join the Peace Corps -... |
 |
Compiled 1981-84 Malaria! (Primary Contributor) |
 |
Parasites! - The Malaria Parasite by Sheila Wyborny (Author) Malaria is a serious disease caused by a tiny mosquito-borne parasite called Plasmodium. It once affected entire empires, but thanks to the work of health organizations, malaria is now mostly confined to warm, moist climates. Scientists are still at work today, however, developing methods of curing the disease and destroying its carriers. |
 |
Molecular Approaches to Malaria by Irwin W. Sherman (Editor) "Molecular Approaches to Malaria" provides an overview of the rapid and significant developments that have occurred in malaria research, including the 2002 genome sequencing of Plasmodium falciparum and its mosquito vector, Anopheles gambiae. This work: provides a concise source of up-to-date research findings; appeals to a diverse audience, including malaria researchers, teachers, investigators, and public health professionals; offers contributions by recognized malaria researchers with practical experience; and, presents comprehensive coverage of topics including a clearly written introduction to Plasmodium molecular biology. |
| © 2009 BrightSurf.com |